Non-fucosylated Anti-Human interferon α/β receptor (anifrolumab) Therapeutic Antibody (CAT#: BioBet-266ZP) Datasheet

IFNAR

anifrolumab;1326232-46-5;MEDI-546;interferon-α/β receptor;IFNAR

Plasma membrane, Lysosome, Endosome

Diseases associated with IFNAR1 include Hepatitis C and Yellow Fever.

Its related pathways are Immune response IFN alpha/beta signaling pathway and Immune response Role of DAP12 receptors in NK cells.

The components of type I interferon receptors, including interferon alpha, IFNB1 and IFNW1. IFNAR2 is generally used as a heterodimer. Type I interferon binding activates the JAK-STAT signaling cascade and triggers the tyrosine phosphorylation of many proteins, including JAKs, TYK2, STAT proteins, and IFNR-and-subunits. It can form an active IFNB1 receptor on its own and activate a signal cascade that does not involve activation of the JAK-STAT pathway (through similarity).

Ubiquitinated, leading to its internalization and degradation (PubMed:14532120, PubMed:15337770). Polyubiquitinated via 'Lys-48'-linked and 'Lys-63'-linked ubiquitin chains, leading to receptor internalization and lysosomal degradation (PubMed:18056411). The 'Lys-63'-linked ubiquitin chains are cleaved off by the BRISC complex (PubMed:24075985). Phosphorylated on serine residues in response to interferon binding; this promotes interaction with FBXW11 and ubiquitination (PubMed:14532120, PubMed:15337770, PubMed:24075985). Phosphorylated on tyrosine residues by TYK2 tyrosine kinase (PubMed:7526154). Phosphorylated on tyrosine residues in response to interferon (PubMed:10049744). Palmitoylation at Cys-463 is required for the activation of STAT1 and STAT2.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1, κ

anifrolumab

Human

Human

Recombinant human monoclonal antibody expressed in CHO binding to human interferon α/β receptor. Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.

Diffuse scleroderma

Diffuse scleroderma